Optimising clinical care through CDH1 -specific germline variant curation: Improvement of clinical assertions and updated curation guidelines

Xi Luo, Jamie L. Maciaszek, Bryony A. Thompson, Huei San Leong, Katherine Dixon, Sónia Sousa, Michael Anderson, Maegan E. Roberts, Kristy Lee, Amanda B. Spurdle, Arjen R. Mensenkamp, Terra Brannan, Carolina Pardo, Liying Zhang, Tina Pesaran, Sainan Wei, Grace Ann Fasaye, Chimene Kesserwan, Brian H. Shirts, Jeremy L. DavisCarla Oliveira, Sharon E. Plon, Kasmintan A. Schrader, Rachid Karam

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Background Germline pathogenic variants in CDH1 are associated with increased risk of diffuse gastric cancer and lobular breast cancer. Risk reduction strategies include consideration of prophylactic surgery, thereby making accurate interpretation of germline CDH1 variants critical for physicians deciding on these procedures. The Clinical Genome Resource (ClinGen) CDH1 Variant Curation Expert Panel (VCEP) developed specifications for CDH1 variant curation with a goal to resolve variants of uncertain significance (VUS) and with ClinVar conflicting interpretations and continues to update these specifications. Methods CDH1 variant classification specifications were modified based on updated genetic testing clinical criteria, new recommendations from ClinGen and expert knowledge from ongoing CDH1 variant curations. The CDH1 VCEP reviewed 273 variants using updated CDH1 specifications and incorporated published and unpublished data provided by diagnostic laboratories. Results Updated CDH1-specific interpretation guidelines include 11 major modifications since the initial specifications from 2018. Using the refined guidelines, 97% (36 of 37) of variants with ClinVar conflicting interpretations were resolved to benign, likely benign, likely pathogenic or pathogenic, and 35% (15 of 43) of VUS were resolved to benign or likely benign. Overall, 88% (239 of 273) of curated variants had non-VUS classifications. To date, variants classified as pathogenic are either nonsense, frameshift, splicing, or affecting the translation initiation codon, and the only missense variants classified as pathogenic or likely pathogenic have been shown to affect splicing. Conclusions The development and evolution of CDH1-specific criteria by the expert panel resulted in decreased uncertain and conflicting interpretations of variants in this clinically actionable gene, which can ultimately lead to more effective clinical management recommendations.

Original languageEnglish
Pages (from-to)568-575
Number of pages8
JournalJournal of Medical Genetics
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2023

Bibliographical note

Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.

Funding

The NIH National Human Genome Research Institute supported this work through U41HG009649 (XL and SP). ABS was supported by an Australian NHMRC Investigator Fellowship (APP177524).

FundersFunder number
National Human Genome Research InstituteU41HG009649
Australian National Health and Medical Research CouncilAPP177524

    Keywords

    • Gastrointestinal Diseases
    • Genetic Predisposition to Disease
    • Genetic Variation
    • Genetics, Medical

    ASJC Scopus subject areas

    • Genetics
    • Genetics(clinical)

    Fingerprint

    Dive into the research topics of 'Optimising clinical care through CDH1 -specific germline variant curation: Improvement of clinical assertions and updated curation guidelines'. Together they form a unique fingerprint.

    Cite this